Proteases involved in MHC class II antigen presentation

Immunological Reviews

Volumn 172, Issue , 1999, Pages 109-120

  Villadangos, José A ^a,e   Bryant, Rebecca A R ^a   Deussing, Jan ^b   Driessen, Christoph ^a   Lennon Duménil, Ana Maria ^a   Riese, Richard J ^c   Roth, Wera ^b   Saftig, Paul ^d   Shi, Guo Ping ^c   Chapman, Harold A ^c   Peters, Christoph ^b   Ploegh, Hidde L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF FREIBURG   (Germany)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CATHEPSIN D; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEINASE; PROTEINASE INHIBITOR;

ANTIGEN BINDING; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BINDING SITE; DENDRITIC CELL; ENDOCYTOSIS; EPITHELIUM CELL; GENETIC ENGINEERING; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYSOSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; T LYMPHOCYTE; THYMOCYTE;

EID: 0033404624     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1999.tb01360.x     Document Type: Article

References (72)

1. 1. Ziegler HK, Unanue ER. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA 1982;79:175-178.
2. 2. Watts C. Capture and processing of exogenous antigens for presentation on MHC molecules. Annu Rev Immunol 1997;15:821-850.
3. 3. Seglen PO, Bohley P. Autophagy and other vacuolar protein degradation mechanisms. Experientia 1992;48:158-172.
4. 4. Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991;353:622-627.
5. 5. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:27-47.
6. 6. Kropshofer H, Hämmerling GJ, Vogt AB. How HLA-DM edits the MHC class II peptide repertoire: survival of the fittest? Immunol Today 1997;18:77-82.
7. 7. Geuze HJ. The role of endosomes and lysosomes in MHC class II functioning. Immunol Today 1998;19:282-287.
8. 8. Brown JH, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-39.
9. 9. Cresswell P. Assembly, transport, and function of MHC class II molecules. Annu Rev Immunol 1994;12:259-293.
10. 10. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378:457-462.
11. 11. Busch R, Cloutier I, Sekaly RP, Hämmerling GJ. Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J 1996;15:418-428.
12. 12. Wolf PR, Ploegh HL. How MHC class II molecules acquire peptide cargo: biosynthesis and trafficking through the endocytic pathway. Annu Rev Cell Dev Biol 1995;11:267-306.
13. 13. Chapman HA. Endosomal proteolysis and MHC class II function. Curr Opin Immunol 1998;10:93-102.
14. 14. Miyazaki T, et al. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 1996;84:531-541.
15. 1 5. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, Van Kaer L. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 1996;84:543-550.
16. 16. Fung-Leung WP, et al. Antigen presentation and T cell development in H2-M-deficient mice. Science 1996;271:1278-1281.
17. 17. Denzin LK, Sant'Angelo DB, Hammond C, Surman MJ, Cresswell P. Negative regulation by HLA-DO of MHC class II-restricted antigen processing. Science 1997;278:106-109.
18. 18. Kropshofer H, et al. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J 1998;17:2971-2981.
19. 19. Diment S, Stahl P. Macrophage endosomes contain proteases which degrade endocytosed protein ligands. J Biol Chem 1985;260:15311-15317.
20. 20. Puri J, Factorovich Y. Selective inhibition of antigen presentation to cloned T cells by protease inhibitors. J Immunol 1988;141:3313-3317.
21. 21. Vidard L, Rock KL, Benacerraf B. The generation of immunogenic peptides can be selectively increased or decreased by proteolytic enzyme inhibitors. J Immunol 1991;147:1786-1791.
22. 22. Adorini L, Guery JC, Fuchs S, Ortiz-Navarrete V, Hämmerling GJ, Momburg F. Processing of endogenously synthesized hen egg-white lysozyme retained in the endoplasmic reticulum or in secretory form gives rise to a similar but not identical set of epitopes recognized by class II-restricted T cells. J Immunol 1993;151:3576-3586.
23. 23. Mizuochi T, Yee ST, Kasai M, Kakiuchi T, Muno D, Kominami E. Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain. Immunol Lett 1994;43:189-193.
24. 24. Manoury-Schwartz B, Chiocchia G, Lotteau V, Fournier C. Selective increased presentation of type II collagen by leupeptin. Int Immunol 1997;9:581-589.
25. 25. Blum JS, Cresswell P. Role for intracellular proteases in the processing and transport of class II HLA antigens. Proc Natl Acad Sci USA 1988;85:3975-3979.
26. 26. Neefjes JJ, Ploegh HL. Inhibition of endosomal proteolytic activity by leupeptin blocks surface expression of MHC class II molecules and their conversion to SDS resistance αβ heterodimers in endosomes. EMBO J 1992;11:411-416.
27. 27. Maric MA, Taylor MD, Blum JS. Endosomal aspartic proteinases are required for invariant-chain processing. Proc Natl Acad Sci USA 1994;91:2171-2175.
28. 28. Morton PA, Zacheis ML, Giacoletto KS, Manning JA, Schwartz BD. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells. J Immunol 1995;154:137-150.
29. 29. Amigorena S, Webster P, Drake J, Newcomb J, Cresswell P, Mellman I. Invariant chain cleavage and peptide loading in major histocompatibility complex class II vesicles. J Exp Med 1995;181:1729-1741.
30. 30. Riese RJ, et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996;4:357-366.
31. 31. Villadangos JA, Riese RJ, Peters C, Chapman HA, Ploegh HL. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J Exp Med 1997;186:549-560.
32. 32. Springer TA, Kaufman JF, Siddoway LA, Mann DL, Strominger JL. Purification of HLA-linked B lymphocyte alloantigens in immunologically active form by preparative sodium dodecyl sulfate-gel electrophoresis and studies on their subunit association. J Biol Chem 1977;252:6201-6207.
33. 33. Sadegh-Nasseri S, Germain RN. A role for peptide in determining MHC class II structure. Nature 1991;353:167-170.
34. 34. Roche PA, Cresswell P. Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules. Proc Natl Acad Sci USA 1991;88:3150-3154.
35. 35. Reyes VE, Lu S, Humphreys RE. Cathepsin B cleavage of Ii from class II MHC α-and β-chains. J Immunol 1991;146:3877-3880.
36. 36. Avva RR, Cresswell P. In vivo and in vitro formation and dissociation of HLA-DR complexes with invariant chain-derived peptides. Immunity 1994;1:763-774.
37. 37. Rodriguez GM, Diment S. Role of cathepsin D in antigen presentation of ovalbumin. J Immunol 1992;149:2894-2898.
38. 38. Van Noort JM, Jacobs MJ. Cathepsin D, but not cathepsin B, releases T cell stimulatory fragments from lysozyme that are functional in the context of multiple murine class II MHC molecules. Eur J Immunol 1994;24:2175-2180.
39. 39. Musil D, et al. The refined 2.15 Å X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J 1991;10:2321-2330.
40. 40. Deussing J, Roth W, Saftig P, Peters C, Ploegh HL, Villadangos JA. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation, Proc Natl Acad Sci USA (In press).
41. 41. Shi GP, Webb AC, Foster KE, Knoll JH, Lemere CA, Munger JS, Chapman HA. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem 1994;269:11530-11536.
42. 42. Chapman HA, Riese RJ, Shi GP. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol 1997;59:63-88.
43. 43. Palmer JT, Rasnick D, Klaus JL, Bromme D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J Med Chem 1995;38:3193-3196.
44. 44. Shi GP, et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 1999;10:197-206.
45. 45. Riese RJ, et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 1998;101:2351-2363.
46. 46. Sanderson F, Thomas C, Neefjes J, Trowsdale J. Association between HLA-DM and HLA-DR in vivo. Immunity 1996;4:87-96.
47. 47. Denzin LK, Hammond C, Cresswell P. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. J Exp Med 1996;184:2153-2165.
48. 48. Kropshofer H, Arndt SO, Moldenhauer G, Hämmerling GJ, Vogt AB. HLA-DM acts as a molecular chaperone and rescues empty HLA-DR molecules at lysosomal pH. Immunity 1997;6:293-302.
49. 49. Nakagawa TY, et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999;10:207-217.
50. 50. Malcherek G, Gnau V, Jung G, Rammensee HG, Melms A. Supermotifs enable natural invariant chain-derived peptides to interact with many major histocompatibility complex-class II molecules. J Exp Med 1995;181:527-536.
51. 51. Sette A, Southwood S, Miller J, Appella E. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med 1995;181:677-683.
52. 52. Stebbins CC, Loss GE Jr, Elias CG, Chervonsky A, Sant AJ. The requirement for DM in class II-restricted antigen presentation and SDS-stable dimer formation is allele and species dependent. J Exp Med 1995;181:223-234.
53. 53. Wolf PR, Tourne S, Miyazaki T, Benoist C, Mathis D, Ploegh HL. The phenotype of H-2M-deficient mice is dependent on the MHC class II molecules expressed. Eur J Immunol 1998;28:2605-2618.
54. 54. Pierre P, Mellman I. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell 1998;93:1135-1145.
55. 55. Abrahamson M. Cystatins. Methods Enzymol 1994;144:685-700.
56. 56. Pierre P, et al. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 1997;388:787-792.
57. 57. Smiley ST, Rudensky AY, Glimcher LH, Grusby MJ. Truncation of the class II β-chain cytoplasmic domain influences the level of class II/invariant chain-derived peptide complexes. Proc Natl Acad Sci USA 1996;93:241-244.
58. 58. Lenarcic B, Bevec T. Thyropins-new structurally related proteinase inhibitors. Biol Chem 1998;379:105-111.
59. 59. Ogrinc T, Dolenc I, Ritonja A, Turk V. Purification of the complex of cathepsin L and the MHC class II-associated invariant chain fragment from human kidney. FEBS Lett 1993;336:555-559.
60. + T cell function in mice lacking the p41 isoform of invariant chain. Immunity 1995;3:385-396.
61. 61. Fineschi B, Sakaguchi K, Appella E, Miller J. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain. J Immunol 1996;157:3211-3215.
62. 6 2. Fineschi B, Arneson LS, Naujokas MF, Miller J. Proteolysis of major histocompatibility complex class II-associated invariant chain is regulated by the alternatively spliced gene product, p41. Proc Natl Acad Sci USA 1995;92:10257-10261.
63. 63. Bevec T, Stoka V, Pungercic G, Dolenc I, Turk V. Major histocompatibility complex class II-associated p41 invariant chain fragment is a strong inhibitor of lysosomal cathepsin L. J Exp Med 1996;183:1331-1338.
64. 64. Nakagawa T, et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science 1998;280:450-453.
65. 65. Mizuochi T, Kasai M, Kokuho T, Kakiuchi T, Hirokawa K. Medullary but not cortical thymic epithelial cells present soluble antigens to helper T cells. J Exp Med 1992;175:1601-1605.
66. 66. Castellino F, Germain RN. Extensive trafficking of MHC class II-invariant chain complexes in the endocytic pathway and appearance of peptide-loaded class II in multiple compartments. Immunity 1995;2:73-88.
67. 67. Ferrari G, Knight AM, Watts C, Pieters J. Distinct intracellular compartments involved in invariant chain degradation and antigenic peptide loading of major histocompatibility complex (MHC) class II molecules. J Cell Biol 1997;139:1433-1446.
68. +-ATPases in the secretory pathway of HepG2 cells. J Biol Chem 1993;268:19092-19100.
69. 69. Van Weert AW, Dunn KW, Gueze HJ, Maxfield FR, Stoorvogel W. Transport from late endosomes to lysosomes, but not sorting of integral membrane proteins in endosomes, depends on the vacuolar proton pump. J Cell Biol 1995;130:821-834.
70. 70. Manoury B, Hewitt EW, Morrice N, Dando PM, Barrett AJ, Watts C. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature 1998;396:695-699.
71. 71. Germain RN, Rinker AG Jr. Peptide binding inhibits protein aggregation of invariant-chain free class II dimers and promotes surface expression of occupied molecules. Nature 1993;363:725-728.
72. 72. Bogyo M, Ploegh HL. Antigen presentation. A protease draws first blood. Nature 1998;396:625, 627.